Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Net Cash Flow: 2021-2022

Historic Net Cash Flow for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to -$1.3 million.

  • Cardiol Therapeutics' Net Cash Flow rose 59.06% to -$1.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $32.3 million, marking a year-over-year change of. This contributed to the annual value of -$4.6 million for FY2024, which is 75.69% up from last year.
  • As of Q3 2022, Cardiol Therapeutics' Net Cash Flow stood at -$1.3 million, which was up 35.01% from -$2.0 million recorded in Q2 2022.
  • Over the past 5 years, Cardiol Therapeutics' Net Cash Flow peaked at $43.8 million during Q4 2021, and registered a low of -$8.2 million during Q1 2022.
  • In the last 2 years, Cardiol Therapeutics' Net Cash Flow had a median value of -$1.3 million in 2022 and averaged $6.3 million.
  • Within the past 5 years, the most significant YoY rise in Cardiol Therapeutics' Net Cash Flow was 59.06% (2022), while the steepest drop was 362.27% (2022).
  • Over the past 2 years, Cardiol Therapeutics' Net Cash Flow (Quarterly) stood at $43.8 million in 2021, then surged by 59.06% to -$1.3 million in 2022.
  • Its Net Cash Flow stands at -$1.3 million for Q3 2022, versus -$2.0 million for Q2 2022 and -$8.2 million for Q1 2022.